Funding opportunities
2,255 live opportunities from Grants.gov, NIH, NSF, and more.
Biomedical & Health× remove
- Early-Stage Technology Development to Enable Rigorous and Reproducible Fungal Metatranscriptomics in Human Vaginal SamplesNational Institute of Allergy and Infectious DiseasesPA-25-304 closes 5/31/2028up to $255,000activenih
- Feasibility Study of Childhood Gender Nonconformity and Early Risk for Suicidal BehaviorNational Institute of Mental HealthPA-21-235 closes 5/31/2028up to $437,250activenih
- Characterization of striatal dopamine dynamics in Shank3-/- mice during postnatal developmentNational Institute of Mental HealthPA-25-304 closes 5/31/2028up to $437,250activenih
- Transcriptional co-activator PGC-1α promotes anti-tumor immunity in colorectal cancerNational Cancer InstitutePA-25-304 closes 5/31/2028up to $388,901activenih
- Iron deficiency and neuropsychiatric disease risk in 3q29 deletion syndromeNational Institute of Mental HealthPA-25-304 closes 5/31/2028up to $456,864activenih
- Assessing the Role of HIV-specific IgA glycosylation on transport and functionNational Institute of Allergy and Infectious DiseasesPA-25-304 closes 5/31/2028up to $269,500activenih
- Multi-level drivers of pregnancy-related cardiovascular outcomes across the life-courseNational Heart Lung and Blood InstitutePA-24-194 closes 5/31/2028up to $165,887activenih
- Precision Liver Cancer Modeling by CRISPR Editing of Primary Human HepatocytesNational Cancer InstitutePAR-25-139 closes 5/31/2028up to $412,249activenih
- Multifaceted Immunomodulatory Self-Healing Glue for Treatment of Chronic WoundsNational Institute of Arthritis and Musculoskeletal and Skin DiseasesPA-25-304 closes 5/31/2028up to $368,156activenih
- Development of methods for robust gene integration into native gut E. coliNational Institute of Allergy and Infectious DiseasesPA-25-304 closes 5/31/2028up to $438,625activenih
- Pathways and Mechanisms of Drug Resistance Evolution in HIVNational Institute of Allergy and Infectious DiseasesPA-24-194 closes 5/31/2028up to $161,868activenih
- Dual Targeting of Inflammation and Fibrosis in DMD with CAR-T TherapyNational Institute of Arthritis and Musculoskeletal and Skin DiseasesPA-25-304 closes 5/31/2028up to $377,506activenih
- Investigation of a novel mycovirus and its impacts on the biology and pathogenesis of Cryptococcus neoformansNational Institute of Allergy and Infectious DiseasesPA-25-304 closes 5/31/2028up to $242,250activenih
- Use of scnn1b transgenic mice to develop new vaccines against pulmonary Mycobacterium aviumNational Institute of Allergy and Infectious DiseasesPA-25-304 closes 5/31/2028up to $423,500activenih
- Targeting post-fusion influenza hemagglutinin to make a better flu vaccineNational Institute of Allergy and Infectious DiseasesPA-24-194 closes 5/31/2028up to $160,609activenih
- Improving the quality and acceptability of autism servicesNational Institute of Mental HealthPA-24-193 closes 5/31/2028up to $123,498activenih
- Proyecto VIDA (VIH Información Distribución y Acción): A Longitudinal Study of HIV Incidence and Engagement in HIV Prevention and Care Among MSM in ColombiaNational Institute of Allergy and Infectious DiseasesRFA-AI-24-009 closes 5/31/2028up to $755,199activenih
- Integrated fatty acid profiling unveils a linkage between BMI and efficacy of anti-tumor immunotherapyNational Cancer InstitutePAR-25-135 closes 5/31/2028up to $129,285activenih
- NIH Stage 1/2 Study: Investigating the Feasibility, Usability, and Benefits of Fully Immersive VR Overground Gait Rehabilitation for Stroke SurvivorsEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentPAR-25-124 closes 5/31/2028up to $304,837activenih
- Characterization of Structural Polymorphism in Native Murine Polyomavirus from Mouse CellsNational Institute of Allergy and Infectious DiseasesPA-25-304 closes 5/31/2028up to $222,457activenih
- Microbubble augmentation of immunotherapy in head and neck cancerNational Cancer InstitutePAR-25-139 closes 5/31/2028up to $401,115activenih
- Herpes Simplex Immunotherapeutic Targeting CD8 T cellsNational Institute of Allergy and Infectious DiseasesRFA-AI-24-068 closes 5/31/2028up to $256,074activenih
- PRIME-HIV: Personalized, Real-time Interactive Medical Education in HIV.National Institute of Allergy and Infectious DiseasesPA-25-304 closes 5/31/2028up to $426,823activenih
- Harnessing antibody-driven bioconjugation to modulate immune functionNational Institute of Allergy and Infectious DiseasesPA-24-194 closes 5/31/2028up to $182,196activenih
- Fully recombinant, highly potent heptavalent botulinum antitoxin with ambient temperature stabilityNational Institute of Allergy and Infectious DiseasesRFA-AI-24-080 closes 5/31/2028up to $491,985activenih